Intuitive Surgical’s Valuation Reset Accelerates as a Rival Gains FDA Clearance
Published on 07/23/2026 at 06:12 | Redaktion boerse-global.de
The numbers tell a story of operational strength, yet the market is writing a very different narrative for Intuitive Surgical. The robotic surgery pioneer delivered a second-quarter beat that would typically spark enthusiasm—earnings per share of $2.80 topped estimates by 12 percent, while revenue surged 19 percent to $2.89 billion, coming in 2.5 percent above consensus. But the stock has been punished relentlessly, sliding to within a whisker of a fresh 52-week low on Wednesday, where it closed at €298.85, down 2.6 percent on the session.
The disconnect stems from a deceleration in the company’s most closely watched metric. US da Vinci procedure growth slowed to roughly 12 percent year-over-year in the quarter, the weakest pace since 2021. Management attributed the softness to patients postponing elective, non-cancer surgeries amid economic uncertainty, compounded by the expiration of enhanced premium tax credits under the Affordable Care Act. CFO Jamie Samath described the ACA impact as a “moderate negative effect” on case volumes. Bariatric procedures, meanwhile, are being squeezed by the rising popularity of GLP-1 weight-loss drugs, adding another headwind.
The market’s reaction was swift and severe. The stock has now lost nearly 39 percent since the start of 2026, and the annualized volatility over the past 30 days has surged to 54 percent. The Relative Strength Index sits at 31, deep in oversold territory. Shares are trading 16 percent below their 50-day moving average and nearly 29 percent below the 200-day line—a technical picture that screams distress.
Analyst Targets Slashed Across the Board
The post-earnings analyst response was a cascade of downward revisions. Stifel cut its price target from $670 to $550, while Bernstein lowered from $750 to $685. BofA reduced its target from $515 to $470, Leerink from $573 to $454, and Raymond James from $577 to $483. TD Cowen and Piper Sandler also trimmed, to $485 and $470 respectively. Even RBC Capital, which remains bullish, shaved its target from $600 to $575.
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
Despite the cuts, the consensus remains broadly positive: 21 buy ratings, 7 holds, and just 1 sell, with an average price target of $523.46. William Blair framed the post-earnings sell-off of over 10 percent as a reflection of inflated investor expectations rather than a deterioration in the company’s long-term prospects, maintaining its overweight rating. BMO Capital Markets stood apart by reaffirming its outperform call and $518 target, pointing to the ongoing upgrade cycle to the da Vinci 5 system as a catalyst.
Deutsche Bank is the notable outlier, sticking with its sell rating and a $366 target—far below the broader consensus. The bank’s bearish view underscores the valuation pressure that has gripped the stock. A fair-value model used by one analyst firm reduced its estimate from $565.25 to $501.73, slashing the assumed revenue growth rate from 13.09 percent to 12.14 percent, while the forward price-to-earnings multiple was cut from 53.19 to 45.50.
A Rival Finally Arrives
Adding to the pressure, Johnson & Johnson received FDA clearance for its Ottava surgical robot, marking the first time a major competitor has secured regulatory approval for a system that directly challenges Intuitive’s da Vinci franchise. Ottava is integrated into the operating table and claims to require 30 to 50 percent less floor space than traditional systems. It is cleared for general surgery procedures including gastric bypass, gastrectomy, and appendectomies. J&J plans an initial US launch with select customers, with additional indications and international approvals to follow.
Intuitive still commands a 57.6 percent share of the US robotic surgery market, and most analysts expect it to maintain its dominance given its first-mover advantage and installed base of 11,710 systems. But the competitive landscape is clearly shifting. Medtronic is also pushing its own robotic platform, and the emergence of a well-funded rival with FDA approval introduces a new variable into an already uncertain outlook.
Intuitive Surgical at a turning point? This analysis reveals what investors need to know now.
Institutional Buying Offers a Contrarian Signal
While retail sentiment has soured, some institutional investors are moving in the opposite direction. Denmark’s Danica Pension purchased roughly 28,782 shares in the first quarter, worth about $13.27 million. ABN Amro, PNC, and Sweden’s Andra AP-fonden also added to their positions. On the sell side, EVP Gary Loeb disposed of 400 shares at $424.14.
The stock now trades at roughly 33 times forward earnings, a sharp compression from historical peaks that have exceeded 70 times. That valuation reset, rather than any operational collapse, appears to be the primary driver of this year’s decline. For a company that has weathered eight drawdowns of 30 percent or more since its IPO, the current sell-off fits a familiar pattern for a high-growth but volatile equity. Whether the stock stabilizes will depend on whether procedure growth reaccelerates in coming quarters—and how much market share J&J’s Ottava can actually capture.
Ad
Intuitive Surgical Stock: New Analysis - 23 July
Fresh Intuitive Surgical information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
